Many studies also demonstrated that both primary and secondary prolonged treatments with SAs are able to induce an enduring GH/IGF-1 reduction and a pituitary tumour volume decrease in most patients with acromegaly [11, 12]. This evidence concerns the gene IGF1 and acromegaly.